Your research model needs to reflect that complexity too.
Today, conventional models and systems for translating oncology drugs into clinical trials have not significantly impacted the failure rate seen in the pharmaceutical industry, with greater than 90% of novel therapeutics failing to reach the market - 50% of those due to lack of efficacy in clinical studies.
This trend has continued… until now.
Our in vivo avatars allow us to do what no other model can. We create a virtual biological twin of each patient by replicating polygenic tumor complexity (engineering up to 20 mutations, not just one mutation) into a living, biological system.
We help direct the treatment of cancer patients, enabling the rapid identification of combination therapies to treat polygenic diseases, as well as providing our Biopharma partners with patient-relevant models to test novel therapies and combinations.
We supply avatar models from our “flybrary” of patient models, and/or create models to your specifications, you supply your compounds. Our project team works with you to define the requirements of your study through to project execution and final report. Studies using existing avatars can be completed in less than a month.
Discover novel combinations.
Repurpose existing molecules.
Compare your molecule’s efficacy with standard of cares and competitive molecules.
Investigate response in patient avatars across a population of disease-relevant models.
Relate genomic profiles to response.
Bangi E, Murgia C, Teague AG, Sansom OJ, Cagan RL. Functional exploration of colorectal cancer genomes Using Drosophila. Nat Commun. 2016;7:13615. Published 2016 Nov 29. doi:10.1038/ncomms13615
Bangi E, Ang C, Smibert P, et al. A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer. Sci Adv. 2019;5(5):eaav6528. Published 2019 May 22. doi:10.1126/sciadv.aav6528
To find out more about how we can help you in your drug discovery and development programs, click here to contact us today.
Our technology was developed by the Icahn School of Medicine at Mount Sinai over years of clinical research and is being used to treat patients today. They have discovered that real-world patient tumours are made resistant to single-drug treatments by mutations in several genes, including genes not previously associated with cancer. Such resistant tumours can, however, be effectively addressed with novel combinations of FDA approved drugs. The most effective combinations almost always include non-cancer drugs, and as such offer drug discovery companies a unique opportunity to test and profile novel combinations with both marketed drugs and those in development.